Popular on PrZen
- How Dance Helped Famed Choreographer Joey L. Dowdy Overcome Adversity and Triumph on The Dancefloor! - 367
- Elevate Local Launches to Help Tennessee Small Businesses Grow Online with Expert SEO and Digital Marketing - 267
- Large Strategic Investment from Global Medical Device Manufacturer to Support Clinics Treating Suicidal Depression and PTSD: NRx: (Stock Symbol: NRXP) - 203
- Tec-Masters to Support In-Space Testing of Honda Regenerative Fuel Cell Technology on the International Space Station - 192
- Support Latest Post-Quantum-Cryptography algorithms with Cryptsoft's SDKs - 178
- purelyIV Launches Take-Home B12 Kit to Support Wellness Between IV Therapy Sessions - 117
- Wohler adds two new 12G SDI monitors to their successful range of audio & video monitors, coupled with the launch of four monitors with GPI/O support - 102
- Olga Torres Once Again Recognized as a Top Advisor by Foreign Investment Watch
- Second Edition of Peernovation: Forged by CEOs. Perfected for Teams Now Available
- La Vida Reports 47% Surge in Golden Visa Enquiries Amid UK Tax Concerns
Similar on PrZen
- New York Times Exposé Vindicates CCHR: ADHD Isn't Biological, Says Watchdog
- FeelWise to Exhibit at ATD 2025 International Conference & EXPO in Washington, DC
- Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
- Thrive Cannabis Marketplace Opens New Main Street Dispensary in Las Vegas Arts District
- Blaming Patients: How Failed Treatments Fuel a $51 Billion Brain Device Industry
- Dentist in London Ontario the Explains Expansion of Canadian Dental Care Plan
- Nevada Supreme Court Faces Pivotal Decision in Probate Appeal Involving Alleged Judicial Misconduct and Fiduciary Fraud
- Family Estrangement on the Rise: Therapist Offers Support, Perspective, and Community for Those Affected
- Perfect Body Laser & Aesthetics Launches New Website
- The Ultimate Med Spa Growth Engine: PatientNow and Aesthetix CRM Announce Strategic Integration
NeuraWorx Partners with Corundum Neuroscience to Initiate Clinical Feasibility Study, Develop Innovative Neurological Disease Treatment
PrZen/33556054
EXCELSIOR, Minn. - PrZen -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on PrZen
- AdvisorVault's Consolidated 17a-4 D3P Service® Full Feature Set Available
- Most Common Car Accidents In America
- Co-Creating the Future of ePaper: ZKONG and E Ink at Touch Taiwan 2025
- New York Times Exposé Vindicates CCHR: ADHD Isn't Biological, Says Watchdog
- HISTORIC FIRST The First Belief System In Human History To Formally Enshrine The Innate Divinity Of The Infant As Civilization's Central Moral Axis
- Stuck in Place? Why Homeowners Are Building Up Instead of Moving Out
- Crafting the Sound of VS Pop™: The Vision of CR Srikanth
- Boston Industrial Solutions, Inc., introduces Rubber and Foam Printing Ink
- FeelWise to Exhibit at ATD 2025 International Conference & EXPO in Washington, DC
- Webinar Announcement: Mexico's Evolving AML/CFT Environment: FATF Review and FTO Designations
- Damian Redd's "Caught in a Fantasy" Surpasses 100,000 Views on VEVO/YouTube Following Album Reissue
- "May the Fourth Be With You" Epic Star Wars Day Run/Walk in Alexandria, Va
- Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met
- Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York"
- MoMojo Records announces posthumous album from Kip London
- Guests Can Save 20 Percent on a Florida Keys Vacation Home Rental with KeysCaribbean's 'Last-Minute Booking Discount'
- All-Woman Trial Team Wins Major Verdict in Major Case
- Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
- Thrive Cannabis Marketplace Opens New Main Street Dispensary in Las Vegas Arts District
- ReferFriends.io Officially Launches: A New Global Hub for Sharing and Discovering Referral Codes